BUSINESS

Fluticasone Nasal Spray under Shipment Curbs Due to Quake, Middle East Unrest

February 8, 2024

Four manufacturers of the allergic rhinitis drug fluticasone nasal spray have announced shipment restrictions for their respective versions of the product, citing reasons including the impact of the New Year’s Day earthquake in central Japan and the Middle East crisis.

Nitto Medic, headquartered in Toyama, an area affected by the temblor, announced its shipment curb on February 5. The company decided on the measure as “a significant delay in the manufacturing plan was caused by the impact of the Noto Peninsula earthquake, which compounded the already unstable API supplies resulting from the situations in Israel,” it explained in a letter to healthcare professionals posted on its website.

Kyorin Rimedio and Towa Pharmaceutical, which started restrictions on February 5 and February 6, respectively, both cited contract manufacturer issues. According to their website information, the products subject to the measures this time are being manufactured by Nitto Medic.

Meanwhile, Teva Takeda Pharma, which markets fluticasone nasal spray as authorized generics, announced its curb on February 7, attributing the measure to the impact of shipment restrictions placed by other companies.

Related Article

BUSINESS

By Ken Yoshino

Japan approved its 39-trillion-yen economic stimulus package on November 22. It does not explicitly state that the drug price revision…

By Philip Carrigan

For 25 years, Morunda has been interviewing leaders in Japan’s pharmaceutical and medical device industry. Most country managers typically come from a commercial background, rooted in sales and marketing. It’s rare to find country managers who come from finance or…

A Japanese health ministry panel discussing the generic industry structure on May 22 put together a report in which it…

A Japanese health ministry study group focused on pharmaceutical regulations on March 21 agreed on a policy to encourage the…

The Japanese health ministry on December 22 approved a batch of medicines for additional indications, including Otsuka Pharmaceutical’s atypical antipsychotic Rexulti (brexpiprazole) and Zenyaku Kogyo’s anti-CD20 antibody Rituxan (rituximab).Rexulti is now newly indicated for the treatment of depression and depressive…

Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…

By Yoshinori Sagehashi

The Japanese health ministry’s expert panel tasked to discuss comprehensive policies for the rapid and stable supply of pharmaceuticals generally…

A key Japanese reimbursement policy panel on December 16 approved the government-backed plan for the FY2023 “off-year” drug price revision.…

Authorized generic (AG) strategies taken by innovative drug makers might help soften the impact of generic competition in their businesses but such tactics might also accelerate the application of “G1”/“G2” price cuts for their off-patent brand-name medicines, a Jiho tally…

Japan’s health ministry announced new NHI prices to be applied in April under the FY2022 drug price revision in the official gazette on March 4, with the earlier application of so-called “G1” price cuts to be implemented for the first…